GSK: two-drug HIV regimen maintains HIV viral suppression

(CercleFinance.com) - 84% of patients who switched from their current three- or four-drug antiretroviral regimen to GSK's two-drug regimen maintained HIV viral suppression, the British drugmaker said on Wednesday.


The 148-week, phase III programme demonstrated long-term efficacy and tolerability of Juluca for the treatment of virologically suppressed adults with HIV, according to results presented today at a UK conference.

Juluca has been approved in the EU and the US.

Copyright (c) 2019 CercleFinance.com. All rights reserved.